[go: up one dir, main page]

ZA200800126B - Methods of protecting against apoptosis using lipopeptides - Google Patents

Methods of protecting against apoptosis using lipopeptides

Info

Publication number
ZA200800126B
ZA200800126B ZA200800126A ZA200800126A ZA200800126B ZA 200800126 B ZA200800126 B ZA 200800126B ZA 200800126 A ZA200800126 A ZA 200800126A ZA 200800126 A ZA200800126 A ZA 200800126A ZA 200800126 B ZA200800126 B ZA 200800126B
Authority
ZA
South Africa
Prior art keywords
lipopeptides
methods
protecting against
against apoptosis
apoptosis
Prior art date
Application number
ZA200800126A
Other languages
English (en)
Inventor
Alexander N Shakhov
Gudkov Andrei
Original Assignee
Cleveland Biolabs Inc
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Biolabs Inc, Cleveland Clinic Foundation filed Critical Cleveland Biolabs Inc
Publication of ZA200800126B publication Critical patent/ZA200800126B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA200800126A 2005-06-13 2008-01-04 Methods of protecting against apoptosis using lipopeptides ZA200800126B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68981005P 2005-06-13 2005-06-13

Publications (1)

Publication Number Publication Date
ZA200800126B true ZA200800126B (en) 2009-10-28

Family

ID=37571018

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200800126A ZA200800126B (en) 2005-06-13 2008-01-04 Methods of protecting against apoptosis using lipopeptides

Country Status (16)

Country Link
US (4) US8008260B2 (fr)
EP (2) EP2554181B1 (fr)
JP (1) JP5000644B2 (fr)
KR (2) KR20080030566A (fr)
CN (1) CN101242852B (fr)
AU (1) AU2006259630B2 (fr)
BR (1) BRPI0611586A2 (fr)
CA (1) CA2612102C (fr)
EA (1) EA014644B1 (fr)
ES (2) ES2421447T3 (fr)
IL (1) IL188091A (fr)
MX (1) MX2007015834A (fr)
NZ (1) NZ565063A (fr)
PT (1) PT1904084E (fr)
WO (1) WO2006138238A2 (fr)
ZA (1) ZA200800126B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118162A1 (en) 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
US9457070B2 (en) 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
BRPI0611586A2 (pt) * 2005-06-13 2010-09-21 Cleveland Biolabs Inc métodos de proteção contra apoptose mediante uso de lipopeptìdeos
WO2007147265A1 (fr) * 2006-06-23 2007-12-27 Alethia Biotherapeutics Inc. Séquences de polynucléotides et de polypeptides impliquées dans le cancer
NZ578928A (en) * 2007-01-09 2013-03-28 Cleveland Biolabs Inc Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases
WO2009074569A1 (fr) * 2007-12-11 2009-06-18 Bracco International Bv Composés de ciblage et thérapeutiques avec un espaceur comprenant de la polyproline et microvésicules remplies de gaz comprenant lesdits composés
AU2009287339B2 (en) * 2008-08-28 2015-11-26 The University Of Queensland Mutant bacterial glycoproteins and uses thereof
CA2737431C (fr) * 2008-09-18 2016-03-29 Nippon Zoki Pharmaceutical Co., Ltd. Derive d'acide amine
CA3050455A1 (fr) 2008-11-03 2010-06-03 Adc Therapeutics Sa Anticorps qui bloquent specifiquement l'activite biologique d'un antigene tumoral
US8404444B2 (en) * 2009-02-25 2013-03-26 Diacarta Llc Method for predicting the level of damage to cells by measuring free circulating Alu nucleic acid
JP5210405B2 (ja) * 2010-03-17 2013-06-12 日本臓器製薬株式会社 アミノ酸誘導体を含有する医薬及び該誘導体の製造方法
EP2490021A1 (fr) 2011-02-18 2012-08-22 Biotempt B.V. Modulateurs de signalisation PRR et GPCR
EP2683398A1 (fr) 2011-03-11 2014-01-15 Omni Bio Pharmaceutical, Inc. Compositions, procédés et utilisations d'agents radioprotecteurs
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
DE102011018499A1 (de) * 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
IN2014CN04690A (fr) 2012-01-09 2015-09-18 Alethia Biotherapeutics Inc
JP5686841B2 (ja) * 2013-04-26 2015-03-18 フレゼニウス メディカル ケア ドイッチェランド ゲゼルシャフト ミット ベシュレンクテル ハフツング 損傷しまたは傷害を受けた組織または臓器の内皮／上皮再生用医薬の製造のための、幹細胞由来微小胞（ｍｖ）の使用ならびにインビトロおよびインビボでの関連した方法
US20160287553A1 (en) 2013-11-22 2016-10-06 Deutsches Krebsforschungszentrum Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
WO2016073733A1 (fr) * 2014-11-06 2016-05-12 Cleveland Biolabs, Inc. Méthodes de traitement du cancer à l'aide de lipopeptides
CN112851755B (zh) * 2021-01-13 2023-09-01 中国人民解放军军事科学院军事医学研究院 一种线性脂肽化合物及其制备方法与应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0000330B1 (fr) 1977-06-20 1981-08-05 Ciba-Geigy Ag Lipopeptides, procédé pour leur préparation et compositions pharmaceutiques les contenant
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5192553A (en) 1987-11-12 1993-03-09 Biocyte Corporation Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
AU666789B2 (en) 1992-12-28 1996-02-22 Takeda Chemical Industries Ltd. 2-amino-6,7-dihydroxy-4-thiaheptanoic acid derivatives, production and use thereof
EP0604945A1 (fr) * 1992-12-28 1994-07-06 Takeda Chemical Industries, Ltd. TAN-1511, dérivés, préparation et utilisation
US5449761A (en) 1993-09-28 1995-09-12 Cytogen Corporation Metal-binding targeted polypeptide constructs
AU1170595A (en) 1993-11-04 1995-05-23 Cytoclonal Pharmaceutics, Inc. A fusion protein and method for making and using same
AU2214199A (en) * 1998-01-07 1999-07-26 Jenner Biotherapies, Inc. Therapeutic liposome-encapsulated immunomodulators
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
DE19822820A1 (de) 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
US20030170249A1 (en) * 1999-02-19 2003-09-11 Hakomori Sen-Itiroh Vaccines directed to cancer-associated carbohydrate antigens
EP1175212A1 (fr) * 1999-04-26 2002-01-30 Center For Molecular Medicine And Immunology Utilisation d'antioxydants afin d'alleger la toxicite des rayons de radioimmunotherapie
WO2001036448A2 (fr) * 1999-10-27 2001-05-25 Cel-Sci Corporation Methodes de preparation et composition de constructions peptidiques utiles dans le traitement d'etats auto-immunes et de greffes liees a la reaction du greffon contre l'hote
DE10048840A1 (de) * 2000-10-02 2002-04-11 Biotechnolog Forschung Gmbh Verwendung von Lipopeptiden oder Lipoproteinen zur Behandlung von Lungeninfektionen und -tumoren
US6987102B2 (en) 2001-07-31 2006-01-17 Anormed, Inc. Methods to mobilize progenitor/stem cells
AU2003226777B2 (en) 2002-04-04 2008-05-29 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Use of a lipopeptide or lipoprotein as an adjuvant in therapeutic or prophylactic vaccinations
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
US20040259790A1 (en) * 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
US20050163764A1 (en) * 2003-09-22 2005-07-28 Yale University Treatment with agonists of toll-like receptors
SI1706133T1 (sl) 2003-12-02 2011-02-28 Cleveland Clilic Foundation Postopki zaščite proti sevanju z uporabo flagelina
WO2005056041A2 (fr) 2003-12-02 2005-06-23 Cleveland Clinic Foundation Methodes d'inhibition apoptotique au moyen de tgf$g(b) latent
US20060039895A1 (en) * 2004-02-28 2006-02-23 Large Scale Biology Corporation Ex-vivo rescue of hematopoietic stem cells after lethal irradiation
BRPI0611586A2 (pt) 2005-06-13 2010-09-21 Cleveland Biolabs Inc métodos de proteção contra apoptose mediante uso de lipopeptìdeos
NZ578928A (en) 2007-01-09 2013-03-28 Cleveland Biolabs Inc Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases

Also Published As

Publication number Publication date
CA2612102C (fr) 2016-02-09
US20090214467A1 (en) 2009-08-27
ES2421447T3 (es) 2013-09-02
KR101604799B1 (ko) 2016-03-28
EP1904084B1 (fr) 2013-04-24
EP2554181A2 (fr) 2013-02-06
US8524668B2 (en) 2013-09-03
AU2006259630A1 (en) 2006-12-28
US9006183B2 (en) 2015-04-14
US20110237507A1 (en) 2011-09-29
HK1123495A1 (en) 2009-06-19
EA200702510A1 (ru) 2008-06-30
JP2008543847A (ja) 2008-12-04
IL188091A (en) 2014-06-30
PT1904084E (pt) 2013-07-22
BRPI0611586A2 (pt) 2010-09-21
CA2612102A1 (fr) 2006-12-28
EP1904084A2 (fr) 2008-04-02
WO2006138238A3 (fr) 2007-07-19
IL188091A0 (en) 2008-03-20
NZ565063A (en) 2011-04-29
US20150306168A1 (en) 2015-10-29
KR20140041874A (ko) 2014-04-04
EP1904084A4 (fr) 2012-03-21
ES2539490T3 (es) 2015-07-01
US9381225B2 (en) 2016-07-05
US8008260B2 (en) 2011-08-30
KR20080030566A (ko) 2008-04-04
HK1181684A1 (en) 2013-11-15
EA014644B1 (ru) 2010-12-30
MX2007015834A (es) 2008-09-15
CN101242852A (zh) 2008-08-13
AU2006259630B2 (en) 2011-10-27
US20140045750A1 (en) 2014-02-13
WO2006138238A2 (fr) 2006-12-28
EP2554181A3 (fr) 2013-03-13
CN101242852B (zh) 2012-10-10
JP5000644B2 (ja) 2012-08-15
EP2554181B1 (fr) 2015-03-18

Similar Documents

Publication Publication Date Title
ZA200800126B (en) Methods of protecting against apoptosis using lipopeptides
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
AP2870A (en) Odcase inhibitors for the treatment of malaria
IL185757A0 (en) Methods of decreasing calcifcation
EP1874731A4 (fr) Analogues de quinobenzoxazines et procedes d'utilisation de ceux-ci
ZA200902300B (en) Use of modified cyclosporins
ZA200709674B (en) Use of prochloraz for wood protection
DK2392335T3 (en) Use of 24-norUDCA
GB0718650D0 (en) Protection sleeve
EP1890761A4 (fr) Methodes permettant d'augmenter la lipolyse
GB0603513D0 (en) Protecting sleepsuit
IL194798A0 (en) Treatment of melanoma
GB0510013D0 (en) Interaction of SNEV
GB0517792D0 (en) Instrument protection
GB0509544D0 (en) Shower protected airer
HUP0500461A3 (en) Pyperazine derivatives of alkyl-oxindoles
HU0500175V0 (en) Assembly for protecting of mattress
GB0512574D0 (en) Uses of (s)-clenbuterol
AU2005906584A0 (en) Use of Inhibitors of Prolyl-4-Hydroxylases
ZA200710971B (en) Elasmobranch-repelling compounds and methods of use
GB0513460D0 (en) Functional restoration of the damaged nervous system
GB0513684D0 (en) Functional restoration of the damaged nervous system